Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Raimund Buller"'
Autor:
Andreas Meyer-Lindenberg, Jacob Nielsen, Pedro Such, Ole Michael Lemming, Janos Zambori, Raimund Buller, Christoph von der Goltz
Publikováno v:
European Neuropsychopharmacology. 61:4-14
Lu AF11167 is a selective, high-affinity inhibitor of PDE10A that modulates dopamine D1 and D2 receptor-mediated intraneuronal signalling without binding to these receptors. This randomized, double-blind, parallel-group, placebo-controlled study (NCT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9036d76b0caa39f7ff24e4674388370
https://doi.org/10.1016/j.euroneuro.2022.05.009
https://doi.org/10.1016/j.euroneuro.2022.05.009
Autor:
Anne Krogh Nøhr, Samuel Demharter, Morana Vitezic, Ida Moltke, Raimund Buller, Anders Albrechtsen, Annika Forsingdal, Morten Lindow, Troels Nielsen
Publikováno v:
Neuropsychopharmacology
Nøhr, A K, Lindow, M, Forsingdal, A, Demharter, S, Nielsen, T, Buller, R, Moltke, I, Vitezic, M & Albrechtsen, A 2021, ' A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with major depressive disorder ', Neuropsychopharmacology, vol. 46, no. 7, pp. 1324-1332 . https://doi.org/10.1038/s41386-021-01002-9
Nøhr, A K, Lindow, M, Forsingdal, A, Demharter, S, Nielsen, T, Buller, R, Moltke, I, Vitezic, M & Albrechtsen, A 2021, ' A large-scale genome-wide gene expression analysis in peripheral blood identifies very few differentially expressed genes related to antidepressant treatment and response in patients with major depressive disorder ', Neuropsychopharmacology, vol. 46, no. 7, pp. 1324-1332 . https://doi.org/10.1038/s41386-021-01002-9
A better understanding of the biological factors underlying antidepressant treatment in patients with major depressive disorder (MDD) is needed. We perform gene expression analyses and explore sources of variability in peripheral blood related to ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51d8195f4ef5544a9909a7d7cdecce52
http://europepmc.org/articles/PMC8134553
http://europepmc.org/articles/PMC8134553
Autor:
Raimund Buller, Stinus Lindgreen, Anne Krogh Nøhr, Mary Hobart, Hans Eriksson, Ida Moltke, Anders Albrechtsen
Publikováno v:
Nøhr, A K, Eriksson, H, Hobart, M, Moltke, I, Buller, R, Albrechtsen, A & Lindgreen, S 2021, ' Predictors and trajectories of treatment response to SSRIs in patients suffering from PTSD ', Psychiatry Research, vol. 301, 113964 . https://doi.org/10.1016/j.psychres.2021.113964
Paroxetine and sertraline are the only FDA approved drugs for treatment of posttraumatic stress disorder (PTSD). Although both drugs show better outcomes than placebo, not all patients benefit from treatment. We examined predictors and latent classes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9955774c6937e975611b124c03edf3ec
https://doi.org/10.1016/j.psychres.2021.113964
https://doi.org/10.1016/j.psychres.2021.113964
Autor:
Carlos Forray, Raimund Buller
Publikováno v:
Biochemical pharmacology. 143
In spite of the significant impact that the serendipitous discovery of drugs with antipsychotic properties had on the care of patients with psychotic disorders, there are significant challenges when aiming at therapeutic goals such as remission, reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839da3da496254e709cb22ee9366b737
https://pubmed.ncbi.nlm.nih.gov/28522405
https://pubmed.ncbi.nlm.nih.gov/28522405
Autor:
Christophe Sapin, Raimund Buller
Publikováno v:
Beyond Assessment of Quality of Life in Schizophrenia ISBN: 9783319300597
Quality of life (QoL) assessments illustrate the patients’ subjective views and needs and can play a key role in drug development of treatments for schizophrenia. So far, QoL data from trials with antipsychotics are mainly used for commercial and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a083b33c671d2a75ec999a417252363
https://doi.org/10.1007/978-3-319-30061-0_11
https://doi.org/10.1007/978-3-319-30061-0_11
Autor:
Raimund Buller, Valérie Legrand
Publikováno v:
Drug Discovery Today. 6:1220-1230
Anxiety and depressive disorders are the most common psychiatric conditions. The medical need for newer, better-tolerated and more efficacious treatments remains high. However, drug development is time-consuming and has a high rate of failed or incon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36065eeb35ffbc3595249787e64fd632
https://doi.org/10.1016/s1359-6446(01)02043-8
https://doi.org/10.1016/s1359-6446(01)02043-8
Autor:
Raimund Buller
Publikováno v:
Clinical Neuropharmacology. 18:S38-S44
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d958f9709ef07fa2356efc654b393888
https://doi.org/10.1097/00002826-199518002-00006
https://doi.org/10.1097/00002826-199518002-00006
Autor:
Sanjay Dubé, Raimund Buller, Megan M. Fredrick, Nina R. Schooler, Maureen Rubin, Nancy M. Peters, Dawn I. Velligan, Judith Jaeger, Jim Mintz, Keith H. Nuechterlein, Stephen R. Marder
Publikováno v:
Schizophrenia bulletin. 38(3)
The Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative was designed to encourage the development of cognitive enhancing agents for schizophrenia. For a medication to receive this indication, regulatory agencies requir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fb4f577a7ee930ea3a4f4a00fc949ff
https://pubmed.ncbi.nlm.nih.gov/21134973
https://pubmed.ncbi.nlm.nih.gov/21134973
Publikováno v:
Expert review of neurotherapeutics. 3(2)
Anxious depressives refers to a group of patients with a primary depressive disorder, who also have significant symptoms of anxiety. Despite the fact that this group of patients is widely recognized and understood to have a poorer prognosis, this gro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a3f3d5fee4bbdd5dbeb222d2592e80
https://pubmed.ncbi.nlm.nih.gov/19810836
https://pubmed.ncbi.nlm.nih.gov/19810836
Autor:
Raimund Buller, Jorga M. Karin
Publikováno v:
Anxiolytics ISBN: 9783034895811
In the mid-1950s the chance finding of iproniazid’s mood-elevating properties [1] led to the discovery that inhibition of monoamine oxidase (MAO) results in changes in cerebral function. Monoamine oxidase metabolizes and thus inactivates endogenous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87616d6255131236b8c13869951cfe0a
https://doi.org/10.1007/978-3-0348-8470-9_4
https://doi.org/10.1007/978-3-0348-8470-9_4